JP2015502973A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502973A5
JP2015502973A5 JP2014548200A JP2014548200A JP2015502973A5 JP 2015502973 A5 JP2015502973 A5 JP 2015502973A5 JP 2014548200 A JP2014548200 A JP 2014548200A JP 2014548200 A JP2014548200 A JP 2014548200A JP 2015502973 A5 JP2015502973 A5 JP 2015502973A5
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutically acceptable
pharmaceutical composition
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502973A (ja
JP6268341B2 (ja
Filing date
Publication date
Priority claimed from GBGB1122305.4A external-priority patent/GB201122305D0/en
Application filed filed Critical
Publication of JP2015502973A publication Critical patent/JP2015502973A/ja
Publication of JP2015502973A5 publication Critical patent/JP2015502973A5/ja
Application granted granted Critical
Publication of JP6268341B2 publication Critical patent/JP6268341B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548200A 2011-12-23 2012-12-21 新規なラパマイシン類似体 Expired - Fee Related JP6268341B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1122305.4 2011-12-23
GBGB1122305.4A GB201122305D0 (en) 2011-12-23 2011-12-23 Novel compound
PCT/GB2012/053228 WO2013093493A1 (en) 2011-12-23 2012-12-21 Novel rapamycin analogue

Publications (3)

Publication Number Publication Date
JP2015502973A JP2015502973A (ja) 2015-01-29
JP2015502973A5 true JP2015502973A5 (cg-RX-API-DMAC7.html) 2016-02-12
JP6268341B2 JP6268341B2 (ja) 2018-01-31

Family

ID=45573035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548200A Expired - Fee Related JP6268341B2 (ja) 2011-12-23 2012-12-21 新規なラパマイシン類似体

Country Status (9)

Country Link
US (1) US9382266B2 (cg-RX-API-DMAC7.html)
EP (1) EP2797929B1 (cg-RX-API-DMAC7.html)
JP (1) JP6268341B2 (cg-RX-API-DMAC7.html)
DK (1) DK2797929T3 (cg-RX-API-DMAC7.html)
ES (1) ES2664246T3 (cg-RX-API-DMAC7.html)
GB (1) GB201122305D0 (cg-RX-API-DMAC7.html)
NO (1) NO2797929T3 (cg-RX-API-DMAC7.html)
PL (1) PL2797929T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013093493A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
CN110603038A (zh) * 2017-02-10 2019-12-20 塔姆山治疗公司 雷帕霉素类似物
US20210024542A1 (en) * 2018-02-09 2021-01-28 Torcept Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of cancer
US20210369684A1 (en) * 2018-02-09 2021-12-02 Torcept Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of neurodegnerative conditions
US20210030726A1 (en) * 2018-02-09 2021-02-04 Torcept Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of neurodegnerative conditions
DE102020203224A1 (de) 2020-03-12 2021-09-16 Heinrich-Heine-Universität Düsseldorf Inhibition von FKBP1A zur Therapie des Triple-negativen Mammakarzinoms
EP4118431A1 (de) 2020-03-12 2023-01-18 Heinrich-Heine-Universität Düsseldorf Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
WO1992021341A1 (en) 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
GB9318144D0 (en) 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
ATE191218T1 (de) 1993-12-17 2000-04-15 Novartis Ag Rapamycin-derivate als immunosuppressoren
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
DK0833828T3 (da) 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
PT956034E (pt) 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
PT1589031E (pt) * 2002-07-16 2007-11-28 Biotica Tech Ltd Produção de policétidos e outros produtos naturais
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
BRPI0608726A2 (pt) * 2005-03-11 2011-03-15 Biotica Tech Ltd uso de um análogo de 39-desmetoxirapamicina ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
EP2313419A1 (en) * 2008-06-17 2011-04-27 Biotica Technology Limited Novel compounds and methods for their production
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound

Similar Documents

Publication Publication Date Title
JP2015502973A5 (cg-RX-API-DMAC7.html)
JP2017531038A5 (cg-RX-API-DMAC7.html)
RU2015133252A (ru) Лечение возрастной макулярной дегенерации
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2014520072A5 (cg-RX-API-DMAC7.html)
IN2014KN00948A (cg-RX-API-DMAC7.html)
JP2012521994A5 (cg-RX-API-DMAC7.html)
JP2009501732A5 (cg-RX-API-DMAC7.html)
JP2013541514A5 (cg-RX-API-DMAC7.html)
JP2013542261A5 (cg-RX-API-DMAC7.html)
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CA2637765A1 (en) Benzamide and heteroarene derivatives
CA2753382C (en) Hepatitis c virus inhibitors
JP2013522367A5 (cg-RX-API-DMAC7.html)
JP2012144574A5 (cg-RX-API-DMAC7.html)
WO2012122340A8 (en) Soluble guanylate cyclase activators
JP2017524025A5 (cg-RX-API-DMAC7.html)
JP2014500295A5 (cg-RX-API-DMAC7.html)
JP2010138190A5 (cg-RX-API-DMAC7.html)
JP2013542992A5 (cg-RX-API-DMAC7.html)
WO2013059278A3 (en) Hepatitis c virus inhibitors
JP2012513416A5 (cg-RX-API-DMAC7.html)
JP2015051983A5 (cg-RX-API-DMAC7.html)
JP2010526827A5 (cg-RX-API-DMAC7.html)
JP2012144537A5 (cg-RX-API-DMAC7.html)